| pubmed-article:17693653 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C0031809 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C0971473 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C0280100 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C0249042 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C1420841 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C2698300 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C2917367 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C0205464 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C0205460 | lld:lifeskim |
| pubmed-article:17693653 | lifeskim:mentions | umls-concept:C0764377 | lld:lifeskim |
| pubmed-article:17693653 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:17693653 | pubmed:dateCreated | 2007-8-13 | lld:pubmed |
| pubmed-article:17693653 | pubmed:abstractText | Cilengitide, an antiangiogenic agent that inhibits the binding of integrins alpha(nu)beta(3) and alpha(nu)beta(5) to the extracellular matrix, was studied at two dose levels in cancer patients to determine the optimal biological dose. | lld:pubmed |
| pubmed-article:17693653 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17693653 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17693653 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17693653 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17693653 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17693653 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17693653 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17693653 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17693653 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17693653 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17693653 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17693653 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17693653 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17693653 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17693653 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:17693653 | pubmed:issn | 0923-7534 | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:HolderWW | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:BaronAA | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:DavisDD | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:MorrowMM | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:HariharanSS | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:GustafsonDD | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:BascheMM | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:ZaniAA | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:GallemannDD | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:EckhardtS GSG | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:McConkeyDD | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:GoriHH | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:O'BryantC LCL | lld:pubmed |
| pubmed-article:17693653 | pubmed:author | pubmed-author:ColevasDD | lld:pubmed |
| pubmed-article:17693653 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17693653 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:17693653 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17693653 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17693653 | pubmed:pagination | 1400-7 | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:meshHeading | pubmed-meshheading:17693653... | lld:pubmed |
| pubmed-article:17693653 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17693653 | pubmed:articleTitle | Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. | lld:pubmed |
| pubmed-article:17693653 | pubmed:affiliation | University of Colorado Cancer Center, Aurora, CO 80045, USA. | lld:pubmed |
| pubmed-article:17693653 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17693653 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| pubmed-article:17693653 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17693653 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17693653 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17693653 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17693653 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17693653 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17693653 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17693653 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17693653 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17693653 | lld:pubmed |
